Overview

The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is:

• How effective the study drug is Participants will receive either investigational product (SB27 or Keytruda) and chemotherapy every 3 weeks.

Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda.

Eligibility

Inclusion Criteria:

• Male or female ≥ 18 years of age
• Have been diagnosed with stage IV non-squamous NSCLC
• Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
• Agree to use adequate methods of contraception

Exclusion Criteria:

• Unable or unwilling to take folic acid and vitamin B12 supplementation
• Severe hypersensitivity to treatment with another monoclonal antibody, any ingredient contained in SB27 or Keytruda, or any component of platinum-containing compounds or pemetrexed.